Valneva: positive data from a chikungunya vaccine


(CercleFinance.com) – Valneva, a vaccine company, today announced positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553.

Following the announcement of positive immunogenicity and safety data for the Phase 3 study VLA1553-301 in March 2022, Valneva initiated an antibody persistence trial (VLA1553-303) aimed at following a sub- group of participants for a period of at least five years and to confirm the long-term durability of the antibody response after a single vaccination.

This antibody persistence trial involved 363 healthy adult participants who were followed between six and 12 months after vaccination.

99% of participants retained neutralizing antibody titers above the sero-response threshold of 150 twelve months after a single vaccination.

No safety issues were identified during the duration of the follow-up study, confirming the safety profile observed in previous studies.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85